Br J Ophthalmol 89:1363-1367 doi:10.1136/bjo.2005.070888
  • Perspective

Topical ciclosporin in the treatment of ocular surface disorders

  1. S Tatlipinar1,2,
  2. E K Akpek1
  1. 1The Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA
  2. 2Department of Ophthalmology, Pamukkale University School of Medicine, Denizli, Turkey
  1. Correspondence to: Esen Karamursel Akpek MD, Ocular Surface and Dry Eye Clinic, The Wilmer Eye Institute, 600 North Wolfe Street, Maumenee Building 317, Baltimore, MD 21287–9238, USA;
  • Accepted 15 June 2005


Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular surface diseases, with a complex interplay of genetic, environmental, and psychosocial factors. Management of these conditions is often challenging. Topical corticosteroids, with their associated side effects, are the mainstay of current treatments for patients with vision threatening disease. Ciclosporin A is an immunomodulator that specifically inhibits T lymphocyte proliferation. Recently, a topical ciclosporin preparation was approved by the US Food and Drug Administration and became available for use in ophthalmology. Given the increasing use of ciclosporin eye drops, the goal of this article is to provide the reader with an overview of the well established uses of ciclosporin and to help refine the questions that should be addressed by future investigations.


  • Dr Akpek received unrestricted research grant from Allergan Inc, Irvine, CA (see reference 58). She is supported in part by a William and Mary Greve Scholarship from Research to Prevent Blindness.

  • Competing interests: none declared